Viking Therapeutics: What's Next?

Viking Therapeutics' shares plunged 40% following Phase 2 results for its oral obesity drug VK2735, as investors focused on a 28% discontinuation rate despite a robust 12.2% weight loss at 13 weeks. The article posits that tolerability concerns stemmed from aggressive titration, a solvable dosing issue rather than a scientific deficiency. With Phase 3 trials for its injectable VK2735 already underway, Viking's unique dual-format strategy for the same molecule positions it distinctively in the burgeoning obesity market, suggesting the recent sell-off is overdone and creates a compelling opportunity.

Analysis

Viking Therapeutics (VKTX) experienced a significant 40% share price decline following the release of its Phase 2 trial data for oral VK2735, as the market focused on a 28% discontinuation rate due to gastrointestinal side effects. However, this tolerability issue is attributed to an aggressive titration schedule, a factor likely addressable with a refined dosing protocol in a future Phase 2b trial. The efficacy signal itself was exceptionally strong, with the drug achieving 12.2% weight loss in just 13 weeks, a result that compares favorably on a time-adjusted basis to competitors like Eli Lilly and Novo Nordisk. Crucially, Viking's strategy is not solely dependent on the oral formulation. The company has already initiated two large-scale Phase 3 VANQUISH trials for its injectable version of VK2735, which previously demonstrated 14.7% weight loss at 13 weeks with a favorable safety profile. This dual-formulation approach for the same molecule is a key differentiator, potentially allowing for flexible patient regimens and positioning Viking uniquely in a market forecast by Goldman Sachs to reach $95 billion by 2030. The recent stock collapse, creating a disconnect with analyst price targets of $87 to $90, may increase the likelihood of a partnership or acquisition, given the company's $300 million funding need for its registrational program and ongoing interest from major pharmaceutical firms in late-stage obesity assets.

Key Decisions for Investors

• Consider the 40% sell-off as a potential entry point, as the market appears to have overreacted to solvable trial execution issues rather than a fundamental flaw in the drug's efficacy.
• Monitor for key catalysts including feedback from the FDA on the path forward for the oral program and any announcements regarding strategic partnerships or M&A, which are now more probable given the lower valuation.
• Investors should weigh the significant upside potential, highlighted by the dual-formulation strategy and strong efficacy data, against the execution risk associated with upcoming trial milestones and the delay in the oral drug's development timeline.